Sermorelin Dosage & Protocol Guide: Titration, Timing, and Lab Monitoring

The most common mistake I see with sermorelin is not in the choice of peptide — it is in the protocol. People start at the wrong dose, inject at the wrong time of day, skip lab monitoring, or run it continuously until the pituitary stops responding as well as it should. A peptide that works by engaging the hypothalamic-pituitary axis needs to be used in a way that respects that axis.

Sermorelin is also different from most peptides on this site because it has a real regulatory history. It was developed as a medicine, approved in the US for children with growth hormone deficiency, and studied in proper endocrine research [1]. The adult studies, however, were small and short, and nobody has shown that raising growth hormone with sermorelin makes healthy adults live longer or better.

This guide covers starting dose, titration schedule, timing rationale, cycle structure, stacking doses, and how to interpret IGF-1 results, alongside what the trials actually found and what can go wrong. For the underlying mechanism and clinical applications, see Sermorelin Peptide: A Physician’s Guide to Growth Hormone Optimization.

At a Glance

What sermorelin is and what it does

Growth hormone (GH) is released in pulses from the pituitary gland, driven by GHRH from the hypothalamus and held back by somatostatin [4]. The largest pulses come at night during deep sleep. GH acts partly through IGF-1, made mainly in the liver.

Sermorelin is the first 29 amino acids of GHRH. It binds the GHRH receptor on the pituitary and triggers GH release. Because the pituitary’s feedback loops stay intact, GH release from secretagogues remains pulsatile and subject to negative feedback, which is the main theoretical safety argument for them over injected GH [5][6].

Two points are often lost in online protocols. First, GH and IGF-1 fall with age in everyone; that decline is not the same as the disease “adult growth hormone deficiency,” which is diagnosed with stimulation testing by an endocrinologist [7]. Second, raising a hormone level is a surrogate. What matters is whether people feel, function or live better, and that has not been shown for sermorelin in healthy adults.

What the evidence shows

Preclinical and physiology

The physiology of GHRH, somatostatin and GH pulsatility is well characterised in animals and humans [4]. Long-acting GHRH analogues such as CJC-1295 raise GH and IGF-1 for days in healthy adults [9], which shows the axis can be stimulated in a controlled way. That says nothing yet about benefit.

Human

A 2018 review of GH secretagogues concluded that few long-term, rigorously controlled studies have examined their efficacy and safety [6]. That is still the central gap, and it is the context for the protocol below.

Starting Dose: Why Lower Is Smarter

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Sermorelin’s mechanism depends on the pituitary responding appropriately to a GHRH signal. Starting too high can cause transient side effects — flushing, water retention, joint aching — that people wrongly attribute to the peptide rather than to an overly aggressive introduction.

Standard starting dose: 100 mcg subcutaneously before bed, five nights per week.

For older adults (over 65), women in early post-menopause, and people with baseline low body weight, the usual approach is to begin at 100 mcg and hold that dose for 8 weeks before any titration. Pituitary somatotroph reserve declines with age, and the dose-response relationship is less predictable in this group.

For younger adults (35–55) with clearly documented GH decline and no complicating metabolic factors, 150 mcg is a reasonable starting point.

Do not begin at 200 mcg or higher regardless of body weight. The plateau of GH output per microgram of sermorelin is not linear — you are stimulating a biological process, not delivering a drug concentration that scales predictably with mass.

Titration Schedule

Titrate based on IGF-1 response, not symptoms. Subjective improvements (sleep quality, energy) often emerge before IGF-1 moves meaningfully. Use the blood work to guide dose escalation, not the feel-good effect.

General titration framework:

Target IGF-1: Upper quartile of the age-adjusted reference range. Many labs report a wide range (e.g., 90–360 ng/mL for a 45-year-old). Aim for the upper portion — around 250–320 ng/mL for most middle-aged adults — not supraphysiologic values. An IGF-1 above the age-adjusted reference ceiling is a signal to reduce the dose, not celebrate an effect.

Sermorelin rarely pushes IGF-1 above the normal reference range at doses up to 300 mcg, which is one of its primary safety advantages over recombinant HGH. If someone is consistently approaching the upper limit of normal on 200 mcg, that may be their maintenance dose — there is no clinical justification to escalate.

Timing: Why Bedtime Is Non-Negotiable

Growth hormone is not secreted evenly throughout the day. The dominant GH pulse occurs during the first cycle of slow-wave (N3) sleep, typically 60–90 minutes after sleep onset. This pulse is responsible for a disproportionate share of GH’s downstream effects on tissue repair, fat mobilisation, and IGF-1 generation.

Sermorelin’s purpose is to amplify this pulse, not to create a new one at an unphysiologic time. Injecting in the morning or midday misses the synchronized window, delivers the GHRH signal when somatostatin tone is higher, and produces a blunted GH response relative to what the same dose achieves at bedtime.

Practical timing: Inject 30–45 minutes before your intended sleep time. You should not eat for at least 2 hours before the injection. Insulin spike from a recent meal elevates somatostatin, which attenuates GH release — the same reason fasting-state IGF-1 labs are important.

Avoid: Eating carbohydrates within 90 minutes of injection. Alcohol within 3 hours (disrupts slow-wave sleep and GH pulsatility independently).

Twice-Daily Dosing: When and How

Standard sermorelin protocol is once nightly. Twice-daily dosing is used in two circumstances:

1. Inadequate IGF-1 response at 300 mcg nightly — rather than escalating to 400–500 mcg at a single dose, splitting into 150–200 mcg at bedtime and a second 100–150 mcg injection in the early morning (5–6 AM) can augment total daily GH output while maintaining physiologic pulse characteristics.

2. Post-injury or post-surgical recovery — where accelerated tissue repair is the primary goal, a morning dose timed to the natural cortisol peak (which does not oppose GH as strongly as midday somatostatin tone) can add a supplemental anabolic signal.

Twice-daily dosing is not recommended for long-term maintenance without a specific indication. It is harder to sustain, adds injection burden, and the incremental IGF-1 gain over optimized once-nightly dosing is modest for most people.

Cycle Structure: Preserving Pituitary Sensitivity

Continuous, uninterrupted sermorelin use for more than 3–4 months can reduce pituitary sensitivity to GHRH signalling — a form of receptor adaptation rather than true desensitisation. The effect is not dramatic, but IGF-1 values may plateau or drift slightly downward even without dose changes.

Two cycling strategies are commonly used:

5-On / 2-Off Weekly Cycling

Inject Monday through Friday, take Saturday and Sunday off. This is the most commonly used approach. It is easy to sustain, minimises the total number of injections, and appears sufficient to prevent the adaptation plateau. IGF-1 typically remains stable for 6–12 months on this schedule without needing dose adjustments.

3-Month On / 1-Month Off

Run sermorelin continuously for 12 weeks (sometimes 16 weeks for slower responders), then take a full month off before resuming. This is preferred by people who find the weekly two-day break hard to keep, or who notice that their response diminishes particularly quickly.

During the off month, IGF-1 will decline toward baseline. This is expected and represents the restoration of pituitary sensitivity you are seeking. IGF-1 typically returns to pre-treatment baseline within 3–6 weeks of stopping.

Sermorelin + Ipamorelin: Stacking Dosage

Combining sermorelin with ipamorelin — a ghrelin mimetic that acts via a different receptor pathway — produces synergistic GH pulse amplification. The combination generates approximately 2–5× greater GH pulse amplitude than either agent alone at equivalent individual doses.

Standard stacking protocol:

When stacking, reduce the sermorelin dose slightly from what you would use as monotherapy. The synergy means 100 mcg sermorelin + 100 mcg ipamorelin often produces greater GH output than 300 mcg sermorelin alone.

Titrate the combination as a unit — increase by 50 mcg of each peptide per 4–6 weeks if IGF-1 remains below target. The titration ceiling for the combination is typically 200 mcg of each compound. Going higher usually reflects suboptimal timing or dietary factors rather than genuine dose inadequacy.

Note that ipamorelin, unlike sermorelin, was never an approved medicine; the FDA lists it among compounding substances with safety concerns (including a death after IV use), and WADA prohibits it under S2. For a full comparison of stacking sermorelin with CJC-1295 variants versus ipamorelin, see Sermorelin vs CJC-1295: Which Growth Hormone Peptide Is Right for You?.

Age-Specific Dosing Considerations

Adults 35–50

This cohort typically shows the clearest dose-response and the most subjective benefit from sermorelin. The pituitary is still capable of robust GH pulsatility — the problem is declining GHRH signal output from the hypothalamus, which sermorelin directly corrects. Standard titration applies: start at 100–150 mcg, titrate to the upper quartile of the IGF-1 reference range, and expect meaningful response by week 8–12.

Adults 50–65

Pituitary somatotroph reserve begins to decline as a separate factor from hypothalamic GHRH output. The dose-response curve is less steep. People in this range may need higher doses (250–350 mcg) to achieve target IGF-1, or may benefit more from the sermorelin + ipamorelin combination, which engages both the GHRH and ghrelin receptor pathways.

Watch fasting glucose more carefully in this age group. Sermorelin modestly blunts insulin sensitivity — usually clinically insignificant — but people with prediabetes should have glucose and HbA1c monitored alongside IGF-1.

Adults Over 65

Starting dose: 100 mcg five nights per week. Hold this dose for at least 8 weeks and recheck IGF-1 before any titration. The risk of over-correction (IGF-1 pushed to the high end of normal, with attendant fluid retention, carpal tunnel symptoms, or joint discomfort) is higher in this cohort. Maintain IGF-1 in the middle rather than upper quartile of the age-adjusted range if these symptoms appear.

Women and Post-Menopausal Considerations

Women tend to have higher baseline GH pulsatility than men of equivalent age and lower volumes of distribution for peptides. Women may respond at lower doses than men — some achieve target IGF-1 at 100–150 mcg nightly without further escalation.

Post-menopausal women on oestrogen therapy should be aware that oral oestrogens (not transdermal) can reduce IGF-1 by upregulating hepatic clearance. If baseline IGF-1 is lower than expected and oral oestrogen replacement is being used, this is likely a contributor. Transdermal oestradiol does not carry the same effect.

For a broader discussion of peptide therapy in women, see Peptide Therapy for Women: A Physician’s Guide.

Lab Monitoring Panel

When to adjust based on IGF-1:

• IGF-1 below the lower tertile of age-adjusted range after 8 weeks at a given dose → increase by 50 mcg
• IGF-1 in the upper quartile but within reference range → maintain current dose
• IGF-1 at or above the reference ceiling → reduce dose by 50 mcg and recheck in 6 weeks
• IGF-1 above reference ceiling with symptoms (joint swelling, carpal tunnel, fluid retention) → hold sermorelin for 2 weeks, resume at lower dose

Side Effects and Dose-Related Tolerability

Sermorelin is well-tolerated at appropriate doses. Side effects are largely dose-related:

Injection site: Mild transient erythema or tenderness at the injection site is common and not a reason to stop. Rotate sites — abdomen (preferred), thigh, lateral upper arm. Use a 29–31 gauge ½-inch needle.

Flushing and warmth: Occurs in approximately 10–15% of patients after injection, typically lasting 5–15 minutes. Usually resolves with continued use. If persistent or distressing, reduce dose by 50 mcg.

Water retention: Mild puffiness, particularly around the ankles or face, usually indicates the dose is at or slightly above optimal. Reduce by 50 mcg; if it persists, check IGF-1.

Headache: Uncommon, usually transient after the first few injections. If persistent, evaluate for intracranial hypertension (rare but warrants investigation if headaches are severe or positional).

Drowsiness: Injection before bed is intentionally timed to coincide with, and reinforce, sleep onset. Some people notice more rapid sleep onset, which is a desirable effect rather than a side effect.

Elevated fasting glucose: A modest rise (typically 5–10 mg/dL) is expected, mediated by GH-induced hepatic glucose output. Not clinically significant in most people. Monitor in those with prediabetes or insulin resistance.

Known and theoretical risks

• Effects of raised GH/IGF-1. Fluid retention, joint and muscle aches, carpal tunnel symptoms and higher fasting glucose are recognised effects of GH excess and GH therapy [6][7].
• Glucose metabolism. GH opposes insulin. People with prediabetes or diabetes need particular caution.
• Cancer question. IGF-1 promotes cell growth. Whether long-term stimulation of the GH axis in healthy adults changes cancer risk is unknown; people with active or recent cancer should not use GH-axis stimulants outside specialist care.
• Missed diagnoses. Fatigue, weight gain and low libido have many causes, including thyroid disease, sleep apnoea, depression and low testosterone. Treating a lab number can delay the real diagnosis.
• Product quality. Compounded and online products vary. In test purchases of another peptide drug (semaglutide) from illegal online sellers, purity was 7.7 to 14.4 percent against a 99 percent label claim, with endotoxin in every sample [11]. Self-injection also carries infection risk.

Regulatory status

• United States (FDA). Sermorelin was approved as Geref for growth hormone deficiency in children [1]; the branded product is no longer marketed. Sermorelin does not appear on the FDA’s 503A category lists (updated 14 May 2026) or on its safety-risk page for compounding substances. Its position differs from never-approved peptides because it was once an approved medicine, but that does not turn adult “anti-aging” use into an approved indication.
• EU and Germany. Not authorised by the EMA or the BfArM.
• Sport (WADA 2026). Prohibited at all times. Section S2.2.4 names GHRH and its analogues, including sermorelin, CJC-1295 and tesamorelin [8].

When to talk to a physician

Talk to a physician, ideally an endocrinologist, if you have symptoms you think are hormonal, a history of pituitary disease, head injury or cranial radiation, or abnormal hormone results. Adult growth hormone deficiency is a defined diagnosis made with stimulation testing [7], and it is treated with approved medicines and monitoring.

If you are being offered sermorelin “for longevity,” ask what diagnosis it is treating, what the evidence is for that use, and who manufactured the product. If you want to contribute to research on the GH axis and aging, look for registered trials on clinicaltrials.gov or the EU Clinical Trials Register.

The Bottom Line

Sermorelin is a genuine GHRH analogue with an approved history in paediatric endocrinology. The protocol most commonly used today — 100–150 mcg at bedtime, titrated by 50 mcg every 4–6 weeks to 200–300 mcg against IGF-1, with 5-on/2-off or 3-month cycles — rests on that physiology and on small, short trials in older men, not on long-term outcome data. It is banned in sport and not authorised in the EU. Get a diagnosis first, monitor IGF-1 and glucose, and work with a physician who knows the GH axis.

Related Articles

• Sermorelin Peptide: A Physician’s Guide to Growth Hormone Optimization — mechanism, clinical applications, and patient selection
• Sermorelin vs CJC-1295: Which Growth Hormone Peptide Is Right for You? — head-to-head comparison with CJC-1295, Mod GRF 1-29, and tesamorelin
• CJC-1295 + Ipamorelin: Dosage, Timing, and Stacking Protocol — dosage guide for the CJC-1295/ipamorelin combination
• Peptide Stacking Guide — framework for multi-peptide protocols
• Peptide Therapy for Women: A Physician’s Guide — female-specific dosing and hormonal considerations